BSX Shareholders Seek Lead Plaintiff in Boston Scientific Lawsuit

Investors with losses may join class action against medical device maker over alleged securities fraud.

Apr. 17, 2026 at 2:37pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a calculator arranged on a clean, monochromatic background, conceptually representing the abstract corporate strategy and legal risks facing Boston Scientific Corporation.A legal case against Boston Scientific over alleged misleading statements exposes the complex financial and regulatory risks facing the medical device company.NYC Today

The Gross Law Firm has issued a notice to shareholders of Boston Scientific Corporation (NYSE: BSX) regarding a class action lawsuit. The lawsuit alleges that Boston Scientific provided overly positive statements to investors while concealing material information about the true state of its U.S. Electrophysiology (EP) segment, which was experiencing slowing growth and increased competition. This allegedly led to a sharp decline in Boston Scientific's stock price when the company reported disappointing Q4 2025 results and weak 2026 guidance.

Why it matters

This lawsuit represents an attempt by investors to hold Boston Scientific accountable for allegedly misleading the market about the performance of a key business unit. If successful, the class action could result in financial recovery for shareholders who lost money due to the company's alleged fraud. The case also highlights the ongoing scrutiny of public companies' disclosures and the legal risks they face if investors believe they have been misled.

The details

According to the complaint, Boston Scientific's management was aware that the growth rate of its U.S. EP segment was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. However, the company allegedly provided overwhelmingly positive statements to investors while disseminating materially false and misleading information. This allegedly caused investors and analysts to be surprised when Boston Scientific reported a net income miss and underwhelming 2026 guidance, leading to a 17.6% single-day stock price decline.

  • The class period is from July 23, 2025 to February 3, 2026.
  • The deadline for shareholders to seek to be a lead plaintiff is May 4, 2026.

The players

Boston Scientific Corporation

A medical device company that develops, manufactures and markets medical devices for use in various interventional medical specialties.

The Gross Law Firm

A nationally recognized class action law firm that seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock.

Got photos? Submit your photos here. ›

What’s next

The deadline for shareholders to seek to be a lead plaintiff in the class action is May 4, 2026.

The takeaway

This lawsuit highlights the legal risks public companies face if investors believe they have been misled about the performance of their business. The outcome could have significant financial implications for Boston Scientific and provide a potential recovery for shareholders who lost money due to the alleged fraud.